# A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)

> **NCT03374241** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 41 (actual)

## Conditions studied

- Obesity

## Interventions

- **BIOLOGICAL:** HM15211 or Placebo

## Key facts

- **NCT ID:** NCT03374241
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-04
- **Primary completion:** 2018-09-14
- **Final completion:** 2018-09-14
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2025-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03374241

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03374241, "A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03374241. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*